235 related articles for article (PubMed ID: 32988825)
1. Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.
Sadek M; Juhas M; Poirel L; Nordmann P
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988825
[TBL] [Abstract][Full Text] [Related]
2.
Huang YS; Chen PY; Chou PC; Wang JT
Microbiol Spectr; 2023 Jun; 11(3):e0056923. PubMed ID: 37154758
[TBL] [Abstract][Full Text] [Related]
3. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
Livermore DM; Mushtaq S; Vickers A; Woodford N
Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
Alm RA; Johnstone MR; Lahiri SD
J Antimicrob Chemother; 2015 May; 70(5):1420-8. PubMed ID: 25634992
[TBL] [Abstract][Full Text] [Related]
5.
Wang W; Huang S; Zou C; Ding Y; Wang H; Pu S; Liao Y; Du H; Wang D; Chen L; Niu S
Front Cell Infect Microbiol; 2021; 11():755763. PubMed ID: 34778107
[TBL] [Abstract][Full Text] [Related]
6. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales.
Kelley CJ; Kennedy-Mendez A; Walser ON; Thwaites MT; Arhin FF; Pillar CM; Hufnagel DA
Microbiol Spectr; 2022 Dec; 10(6):e0360122. PubMed ID: 36342288
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.
Le Terrier C; Nordmann P; Sadek M; Poirel L
J Antimicrob Chemother; 2023 May; 78(5):1191-1194. PubMed ID: 36921067
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of aztreonam-avibactam and comparators against Metallo-β-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016-2020.
Rossolini GM; Arhin FF; Kantecki M
J Glob Antimicrob Resist; 2024 Mar; 36():123-131. PubMed ID: 38154750
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China.
Zhang B; Zhu Z; Jia W; Qu F; Huang B; Shan B; Yu H; Tang Y; Chen L; Du H
Int J Infect Dis; 2020 Aug; 97():11-18. PubMed ID: 32473388
[TBL] [Abstract][Full Text] [Related]
11.
Cervino I; Gonzalez D; Nastro M; Vega J; Reyes AP; Buriano G; Vay C; Famiglietti A; Rodriguez CH
J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34605763
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of Aztreonam-Avibactam-Resistant NDM-5-Producing Escherichia coli in the Food Chain.
Sadek M; Poirel L; Nordmann P
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0088221. PubMed ID: 34125588
[No Abstract] [Full Text] [Related]
13. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
Le Terrier C; Nordmann P; Poirel L
J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
[TBL] [Abstract][Full Text] [Related]
15. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019.
Rossolini GM; Stone G; Kantecki M; Arhin FF
J Glob Antimicrob Resist; 2022 Sep; 30():214-221. PubMed ID: 35760303
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017.
Estabrook M; Kazmierczak KM; Wise M; Arhin FF; Stone GG; Sahm DF
J Glob Antimicrob Resist; 2021 Mar; 24():316-320. PubMed ID: 33524556
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Falcone M; Daikos GL; Tiseo G; Bassoulis D; Giordano C; Galfo V; Leonildi A; Tagliaferri E; Barnini S; Sani S; Farcomeni A; Ghiadoni L; Menichetti F
Clin Infect Dis; 2021 Jun; 72(11):1871-1878. PubMed ID: 32427286
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the MTS™ aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-β-lactamase-producing Enterobacterales.
Emilie CM; Alice CM; Marine G; Farfour E; Pourbaix A; Dortet L; Lucie L; Marc V
Eur J Clin Microbiol Infect Dis; 2024 Apr; 43(4):777-784. PubMed ID: 38277033
[TBL] [Abstract][Full Text] [Related]
20. Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type β-lactamases in PBP3-modified Escherichia coli.
Helsens N; Sadek M; Le Terrier C; Poirel L; Nordmann P
Eur J Clin Microbiol Infect Dis; 2024 Feb; ():. PubMed ID: 38319508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
